Mycophenolate mofetil in myasthenia gravis: the unanswered question

Bibliography

• Betana M, Kaminski HJ. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review). Neurology 2007;68(1):1-6
   Google Scholar
• Levin KH, Richman DP. Myasthenia gravis. Clin Aspects Autoimmune 1989;4:23
   Google Scholar
• Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow-up study. J Neurol Neurosurg Psychiatry 1989;52(10):1121-7
   PubMed Web of Science ®Google Scholar
• Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 2007;4:1-31
   Google Scholar
• Paszcuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15(3):291-8
   PubMedGoogle Scholar
• Palace J, Newsom-Davis J, Lecky B. Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998;50(6):1778-83
   PubMed Web of Science ®Google Scholar
• Tindall RS, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316(12):719-24
   PubMed Web of Science ®Google Scholar
• Ciafaloni E. Mycophenolate mofetil and myasthenia gravis. Lupus 2005;14(Suppl 1):46-9
   PubMed Web of Science ®Google Scholar
• Schneider-Gold C, Hartung HP, Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve 2006;34(3):284-91
   PubMed Web of Science ®Google Scholar
• Allison AC. Mechanism of mycophenolate mofetil. Lupus 2006;14(Suppl):2-8
   Google Scholar
• Durez P, Apelboom T, Pira C, et al. Anti-inflammatory properties of mycophenolate mofetil in murine endotoxemia: inhibition of TNF-alpha and upregulation of IL-10 release. Int J Immunopharmacol 1999;21(9):581-7
   PubMed Web of Science ®Google Scholar
• Cohn R, Mirkovich A, Dunlap B, et al. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999;68(3):411-8
   PubMed Web of Science ®Google Scholar
• Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007;46(1):13-58
   PubMed Web of Science ®Google Scholar
• Solomons N, Mamelok R. No pharmacokinetic interaction between mycophenolate mofetil and prednisolone in healthy male volunteers. PU018 The 8th International Congress on SLE; 2007; Shanghai, China
   Google Scholar
• Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998;51(3):912-3
   PubMedGoogle Scholar
• Schneider C, Gold R, Reiners K, Toyka KV. Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol 2001;46(2):79-82
   PubMed Web of Science ®Google Scholar
• Mowzoon N, Sussman A, Bradley W. Mycophenolate treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001;185(2):119-22
   PubMed Web of Science ®Google Scholar
• Meriggioli MN, Rowin J. Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle Nerve 2000;23(8):1287-9
   PubMedGoogle Scholar
• Lim AKH, Donnan G, Chambers B, Lerino FL. Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity. Intern Med J 2007;37(1):55-9
   PubMedGoogle Scholar
• Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia-gravis: An open-label pilot study. Neurology 2001;56:97-99
   PubMed Web of Science ®Google Scholar
• Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56(1):94-6
   PubMed Web of Science ®Google Scholar
• Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003;61(10):1438-40
   PubMed Web of Science ®Google Scholar
• Meriggioli MN, Rowin J, Richman J, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann NY Acad Sci 2003;998:494-9
   PubMed Web of Science ®Google Scholar
• The Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394-9
   PubMed Web of Science ®Google Scholar
• Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:400-6
   PubMed Web of Science ®Google Scholar
• Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006;142:1447-54
   PubMed Web of Science ®Google Scholar
• Neurath MF, Wanitschke R, Peters M, et al. Randomized trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's Disease. Gut 1999;44:625-8
   PubMed Web of Science ®Google Scholar